Last updated: February 21, 2026
What is NDC 51672-1308?
NDC 51672-1308 refers to a specific drug identified by the National Drug Code. Exact details, including the generic name, formulation, manufacturer, and approved indications, are necessary to accurately assess the market landscape.
Assumption: Based on publicly available databases, NDC 51672-1308 corresponds to [Drug Name], a [drug class] approved for [indications].
Market Size Overview
The drug's utilization depends on its approved indications, incidence/rate of target conditions, and competitive landscape.
Incidence and Prevalence
- Target Population: Estimated at [X] million patients globally.
- US Market: Approximately [Y] million patients with the condition(s) relevant for this drug.
- Market Penetration Rate: Historically, similar drugs have achieved [Z]% market share within [timeframe].
Competition
- Key Competitors: Includes [Competitor A], [Competitor B], and [Competitor C].
- Market Share Distribution: Competitors hold [X]%, [Y]%, and [Z]% respectively.
Revenue Estimates
Based on market penetration, pricing, and reimbursement:
| Year |
Estimated Patients |
Revenue (USD millions) |
| 2023 |
[X thousand] |
[Y] |
| 2024 |
[X+5%] thousand |
[Z+10%] |
| 2025 |
[X+10%] thousand |
[A] |
Note: These projections assume steady growth, no significant market disruptions, and current reimbursement policies.
Price Projections
Current Pricing (2023)
- Average Wholesale Price (AWP): Approximately $[amount]/unit.
- Estimated List Price: $[amount]/dose.
- Reimbursed Price: Typically [percentage]% of list price due to payor negotiations.
Pricing Trends
- Historical Trends: Similar drugs experienced price increases at [X]% annually over the past 3 years.
- Projected Trends (Next 3 Years): Prices are expected to grow [Y]% annually, driven by inflation, manufacturing costs, and market exclusivity.
Impact of Patent and Exclusivity
- Patent Expiry: Expected in [year].
- Orphan/Exclusivity Status: If applicable, may extend market exclusivity until [year].
- Potential for Biosimilar Entry: If biological, biosimilars may enter around [year], possibly reducing prices by [Z]%.
Regulatory and Reimbursement Factors
- FDA Status: Approved for [indications] since [date].
- Coverage: Reimbursement rate varies, with [X]% of prescriptions covered by Medicare/Medicaid.
- Pricing Regulations: Some markets regulate or cap prices for high-cost medications.
Risks and Opportunities
Risks
- Entry of biosimilars or generics.
- Policy changes reducing pricing flexibility.
- Decreased market share due to new therapies.
Opportunities
- Expansion into new indications or populations.
- Growth in emerging markets.
- Strategic partnerships for market expansion.
Key Takeaways
- Precise market size depends heavily on the drug's indication and competitive positioning.
- Current price points are approximately $[amount]/dose, with growth projections of [X]% annually over the next 3 years.
- Revenue estimates for 2023 are in the range of $[Y] million, with potential to grow as market penetration increases.
- Patent and regulatory environments significantly influence future pricing and market exclusivity.
FAQs
1. What are the main competitors for NDC 51672-1308?
The primary competitors include drugs like [Competitor A] and [Competitor B], which have similar indications and market share.
2. How does patent expiry affect the drug’s pricing?
Patent expiry opens the market to biosimilars or generics, typically reducing prices by [Z]% or more.
3. What factors most influence the drug’s market size?
Prevalence of the target condition, approval in various regions, and physician prescribing habits.
4. How are reimbursement policies impacting the drug’s pricing?
Insurance negotiations and regulatory policies can significantly limit listed prices and reimbursement levels.
5. Are there emerging therapies that threaten this drug’s market?
Yes, recent approvals of novel treatments or biosimilars may decrease market share and reduce pricing power.
References
- [1] U.S. Food and Drug Administration. (2022). [Drug approval details].
- [2] IQVIA. (2022). Market Trends and Sales Data.
- [3] CMS. (2023). Reimbursement Policies for High-cost Drugs.
- [4] Evaluate Pharma. (2023). Price and Revenue Projections for Specialty Drugs.
